Publications

BibTex format

@article{Majewska:2017:10.2217/cns-2017-0001,
author = {Majewska, P and Ioannidis, S and Raza, MH and Tanna, N and Bulbeck, H and Williams, M},
doi = {10.2217/cns-2017-0001},
journal = {CNS Oncology},
pages = {307--313},
title = {Postprogression survival in patients with glioblastoma treated with concurrent chemoradiotherapy: a routine care cohort study},
url = {http://dx.doi.org/10.2217/cns-2017-0001},
volume = {6},
year = {2017}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Glioblastoma is the commonest malignant brain tumor in adults. Most patients develop progressive disease before they die. However, survival after developing progressive disease is infrequently reported. We identified patients with histologically proven disease who were treated with concurrent chemoradiotherapy during 2006–2013. We analyzed overall survival (OS), progression-free survival and postprogression survival (PPS) in relation to age, O6-methylguanine-DNA methyltransferase promoter methylation and extent of surgical resection. We identified 166 patients. Median survival was 13.5 months; 2-year OS was 21.7%. Median progression-free survival and PPS were 7.03 and 4.53 months, respectively. Age and extent of surgical resection were correlated with OS. Only the extent of surgical resection was associated with PPS. Our work suggests that the established prognostic factors for glioblastoma do not appear to help predict PPS.
AU  - Majewska,P
AU  - Ioannidis,S
AU  - Raza,MH
AU  - Tanna,N
AU  - Bulbeck,H
AU  - Williams,M
DO  - 10.2217/cns-2017-0001
EP  - 313
PY  - 2017///
SN  - 2045-0907
SP  - 307
TI  - Postprogression survival in patients with glioblastoma treated with concurrent chemoradiotherapy: a routine care cohort study
T2  - CNS Oncology
UR  - http://dx.doi.org/10.2217/cns-2017-0001
UR  - http://hdl.handle.net/10044/1/65511
VL  - 6
ER  -

Download

DrMatthewWilliams

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)